Human Microbiome Therapeutics Market Regional Outlook, Competitive Strategies & Forecast by 2027

Research / Human Microbiome Therapeutics Market / By /

The latest market intelligence study on the Human Microbiome Therapeutics market performs an extensive analysis of the competitive landscape and growing investment pocket of the Human Microbiome Therapeutics market for the forecast period, 2020 – 2027.

Advertisements
your ads here

The extensive examination of the global business environment provides a detailed analysis of the key driving forces and challenges with the aim to give the stakeholders, business owners, and filed marketing executives a competitive advantage over others.

However, the surging costs of equipment and infrastructure, as well as challenging laboratory bacteria development & isolation procedures, are predicted to restrain market growth in the following years.

Key participants include Oxidien Pharmaceuticals, LLC, DermBiont, Inc, LNC Therapeutics SA, Carbiotix AB, Embion Technologies SA, BiomX Ltd., CoreBiome, Inc., Biotagenics Inc., Commense Inc, and Finch Therapeutics, among others.

The Global Human Microbiome Therapeutics Market is estimated to garner a valuation of USD 1,098.4 Million by 2027, according to the latest assessment by Emergen Research. The industry is speculated to grow substantially with the rising prominence of the market in the sphere of personalized medicine & nutrition. Moreover, technological improvements in the metagenomics sector and the therapeutic system would also impel market growth in the forecast duration.

Emergen Research has categorized the Global Human Microbiome Therapeutics Market based on product, approach, therapeutic area, disease, and region:

  • Product Outlook (Revenue, USD Million; 2017-2027)
    • Prescription Drugs
    • Medical Foods
    • Probiotics
    • Prebiotics
  • Approach Outlook (Revenue, USD Million; 2017-2027)
    • Microbial Consortia
    • Small Molecule Therapies
    • Phage Cocktail
    • Genetically Modified Single Strain Bacteria
    • Microbial Ecosystems
    • Single Strain Whole Bacteria
  • Therapeutic Area Outlook (Revenue, USD Million; 2017-2027)
    • Oncology
    • Dermatological Disorders
    • Autoimmune Disorders
    • Infectious Disease
    • Metabolic Disorders
    • Others
  • Disease Outlook (Revenue, USD Million; 2017-2027)
    • Irritable Bowel Syndrome
    • Crohn’s Disease
    • Diabetes
    • difficile
    • Others

Key Highlights From The Report

The probiotics sub-segment is projected to lead the market with the largest share in the segment. Probiotics are organisms that give certain health benefits when consumed, such as yeasts and bacteria.

The small molecule therapies sub-segment held the leading share in the sector in 2019. Owing to its extensive applications, it is speculated to record the fastest growth in the forecast years.

The infectious disease sub-segment is predicted to lead the therapeutic area segment in the forecast years owing to the increasing prevalence of microbial dysbiosis-based diseases and the increasing usage of antibiotics and drug development for the purposes of microbiome-based treatments.

  • Regional Outlook (Revenue, USD Million; 2017-2027)
    • North America
      1. S.
      2. Canada
      3. Mexico
    • Europe
      1. Germany
      2. K.
      3. France
      4. BENELUX
      5. Rest of Europe
    • Asia Pacific
      1. China
      2. Japan
      3. South Korea
      4. India
      5. Rest of APAC
    • Latin America
      1. Brazil
      2. Rest of LATAM
    • Middle East & Africa
      1. Saudi Arabia
      2. A.E.
      3. Rest of MEA

Related Posts